Latest news with #FCCP
Business Wire
09-06-2025
- Business
- Business Wire
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
MONTREAL--(BUSINESS WIRE)-- Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006 Share Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future. 'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.' Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases. 'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.' About Innospera Pharma Innospera is a Montreal-based biotechnology company developing first-in-class GPR84 and GPR40 modulators to restore homeostasis in diseases driven by metabolic and inflammatory dysfunction. The company's lead compound, ING-006, is a synthetic lipid designed to address Idiopathic Pulmonary Fibrosis (IPF) by resolving inflammation and reducing fibrogenesis. Innospera is backed by a strong syndicate of investors including Investissement Québec, Seido Capital, and Anges Québec. For more information, visit
Associated Press
25-03-2025
- Health
- Associated Press
GO2 for Lung Cancer Forms the Global Advisory Council to Support Its Mission to Confront Lung Cancer
'The diverse range of experiences, expertise, and perspectives this group offers plays a crucial role in advancing our work.' — GO2 for Lung Cancer President and CEO Laurie Ambrose WASHINGTON, DC, UNITED STATES, March 25, 2025 / / -- GO2 for Lung Cancer (GO2) announced it established the Global Advisory Council (GAC), a new group that brings together scientists, medical specialists, and other healthcare professionals from diverse disciplines who focus on GO2's areas of impact: healthcare delivery, patient education, policy, and research. The GAC provides recommendations to guide GO2's program and project development. 'The GAC is an invaluable resource as GO2 for Lung Cancer continues its long-standing mission to increase survival and quality of life for those at risk, diagnosed, and living with lung cancer,' said GO2's President and CEO Laurie Ambrose. 'The diverse range of experiences, expertise, and perspectives this group offers plays a crucial role in advancing our work.' The GAC is the evolution of GO2's Scientific Leadership Board into a broader, multidisciplinary group. While science remains the core foundation, the diversified expertise of GAC members better addresses emerging challenges in lung cancer care, screening access, and patient advocacy. 'I am excited to collaborate with GO2 and colleagues who bring a depth of lung cancer expertise that spans a range of specialties,' said Memorial Cancer Institute's Chief Scientific Officer and Medical Director, Luis E. Raez, MD, FACP, FCCP. 'The GO2 Global Advisory Council is critical to ensuring that we continue to address the needs of the lung cancer community.' As the world's leading organization dedicated to transforming lung cancer survivorship, GO2 is dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer. GAC's members play a pivotal role in advancing GO2's mission and achieving its key objectives: - Increase the number of lung cancers diagnosed early - Increase the rate of biomarker testing and use of precision medicine - Increase the impact of community engagement - Improve quality of life Current members of the GO2 Global Advisory Council include: Trever Bivona, MD, PhD; Professor of Medicine; University of California, San Francisco Hossein Borghaei, DO, MS; Professor and Chief, Thoracic Oncology; Fox Chase Cancer Center Debra S. Dyer, MD, FACR; Professor and Chair, Department of Radiology; National Jewish Health Jan M. Eberth, PhD, FACE; Professor and Chair, Health Management and Policy; Drexel University Jhanelle E. Gray, MD; Chair, Thoracic Oncology; Moffitt Cancer Center Karen Kelly, MD; Chief Executive Officer; International Association for the Study of Lung Cancer Christine M. Lovly, MD, PhD, FASCO; Associate Professor of Medicine, Hematology and Oncology; Vanderbilt University Medical Center William R. Mayfield, MD, FACS; Medical Director, Lung Cancer Screening and Incidental Nodule Programs; Wellstar Health System Peter Mazzone, MD, MPH, FCCP; Head, Thoracic Oncology Program, Pulmonary Department; Cleveland Clinic Kathryn F. Mileham, MD, FACP; Co-Lead, Lung Cancer Disease Group and Chief, Thoracic Medical Oncology Section; Atrium Health – Levine Cancer Institute Drew Moghanaki, MD, MPH; Professor and Chief of Thoracic Oncology; David Geffen School of Medicine at UCLA Ray U. Osarogiagbon, MBBS, FACP; Chief Scientist; Baptist Memorial Healthcare Corporation Jamie S. Ostroff, PhD; Chief, Behavioral Sciences Service; Memorial Sloan Kettering Cancer Center Luis E. Raez, MD, FACP, FCCP; Chief Scientific Officer & Medical Director; Memorial Cancer Institute Natasha Rekhtman, MD, PhD; Attending Pathologist, Thoracic Pathology & Cytopathology; Memorial Sloan Kettering Cancer Center Alison Mayer Sachs, MSW, LSW, CSW, OSW-C, FAOSW; Cancer Support Services Consultant Pamela Samson, MD, MPHS; Assistant Professor, Department of Radiation Oncology; Washington University in Saint Louis Jacob Sands, MD; Physician; Dana-Farber Cancer Institute Kerri B. Susko, LISW-CP, OSW-C; Counselor, Center for Integrative Oncology and Survivorship & Director, Cancer Support Community; Prisma Health Cancer Institute Jennifer Temel, MD; Professor of Medicine; Massachusetts General Hospital Douglas E. Wood, MD, FACS, FRCSEd; The Henry N. Harkins Professor and Chair, Department of Surgery; University of Washington ABOUT GO2 FOR LUNG CANCER GO2 for Lung Cancer relentlessly confronts lung cancer on every front, every day, for everyone. Founded by patients and survivors, GO2 is dedicated to increasing survival and quality of life for those at risk, diagnosed, and living with lung cancer. For more information, visit Facebook (@GO2forLungCancer), Instagram, X (formerly Twitter, @go2forlungcancr), and LinkedIn (@go2forlungcancer). Julia Spiess X LinkedIn Instagram YouTube Legal Disclaimer:
